Chronic Myeloid Leukemia
Discovery pinpoints cause of two types of leukemia, providing insights into new treatment approach
(Medical Xpress)—Patients with two forms of leukemia, who currently have no viable treatment options, may benefit from existing drugs developed for different types of cancer, according to a study conducted by researchers ...
Cancer
May 10, 2013 |
5 / 5 (1) |
0
|
Mutations in CSF3R common in CNL, atypical CML
(HealthDay)—In the war against cancer, it looks like matchmaking—between genes and drugs—could be an important tool, according to new research into the genetic underpinnings of two rare forms of leukemia.
Cancer
May 09, 2013 |
not rated yet |
0
Doctors say cancer drug costs are too high
More than 100 doctors from around the world have signed a letter decrying the high cost of cancer drugs which reach $100,000 per year or more, and calling for pharmaceutical companies to ease prices.
Medications
Apr 26, 2013 |
5 / 5 (4) |
2
Leading leukemia experts: High leukemia treatment costs may be harming patients
The increasing cost of treatments for chronic myeloid leukemia (CML) in the United States has reached unsustainably high levels and may be leaving many patients under- or untreated because they cannot afford care, according ...
Cancer
Apr 25, 2013 |
not rated yet |
0
Three cancer scientists awarded $500K Nmedical prize
Three scientists at universities in Pennsylvania, Illinois and Oregon whose research has helped transform cancer treatment will share one of the richest prizes in medicine and biomedical research.
Cancer
Apr 16, 2013 |
5 / 5 (2) |
0
Drug maker Novartis loses India patent battle (Update)
India's Supreme Court on Monday rejected drug maker Novartis AG's attempt to patent an updated version of a cancer drug in a landmark decision that health activists say ensures poor patients around the world ...
Medications
Apr 01, 2013 |
5 / 5 (3) |
0
India's top court to deliver Novartis judgment
India's Supreme Court is to rule Monday on a landmark patent case involving Swiss drugmaker Novartis AG that focuses on demands by major companies that their investments be protected, against Indian companies ...
Medications
Mar 31, 2013 |
not rated yet |
0
Gleevec's latest approval is for pediatric cancer
(HealthDay)—The anti-cancer drug Gleevec (imatinib) has received new U.S. Food and Drug Administration approval to treat the most common type of pediatric cancer, affecting some 2,900 children each year, the agency said ...
Cancer
Jan 25, 2013 |
not rated yet |
0
Study of cancer cell metabolism yields new insights on leukemia
University of Rochester Medical Center scientists have proposed a new reason why acute myeloid leukemia, one of the most aggressive cancers, is so difficult to cure: a subset of cells that drive the disease appear to have ...
Cancer
Jan 17, 2013 |
not rated yet |
0
Drug targets hard-to-reach leukemia stem cells responsible for relapses
Researchers at the University of California, San Diego School of Medicine have discovered that hard-to-reach, drug-resistant leukemia stem cells (LSCs) that overexpress multiple pro-survival protein forms ...
Cancer
Jan 17, 2013 |
3.7 / 5 (3) |
0
|
Enzyme accelerates malignant stem cell cloning in chronic myeloid leukemia
An international team, headed by researchers at the University of California, San Diego School of Medicine, has identified a key enzyme in the reprogramming process that promotes malignant stem cell cloning ...
Cancer
Dec 24, 2012 |
5 / 5 (1) |
0
|
Options increase for CML patients failed by existing drugs
The U.S. Food and Drug Administration (FDA) this month expanded the options for patients with chronic myeloid leukemia and one form of acute lymphoblastic leukemia that carries the Philadelphia chromosome (Ph+ALL). It approved ...
Cancer
Dec 21, 2012 |
not rated yet |
0
Iclusig approved for rare leukemias
(HealthDay)—Iclusig (ponatinib) has been approved by the U.S. Food and Drug Administration to treat two rare forms of leukemia..
Cancer
Dec 16, 2012 |
not rated yet |
0
Temple scientists target DNA repair to eradicate leukemia stem cells
Despite treatment with imatinib, a successful drug that targets chronic myeloid leukemia (CML), a deadly type of cancer, some patients may continue to be at risk for relapse because a tiny pool of stem cells is resistant ...
Cancer
Dec 09, 2012 |
5 / 5 (3) |
0
|
ATRA and arsenic trioxide versus ATRA and idarubicin for newly diagnosed, non high-risk acute promyelocytic
New research demonstrates the efficacy of the first curative treatment for acute promyelocytic leukemia (APL) that does not include chemotherapy, marking an important step toward front-line use of targeted therapies for acute ...
Cancer
Dec 09, 2012 |
not rated yet |
0
Chronic myelogenous (or myeloid) leukemia (CML), also known as chronic granulocytic leukemia (CGL), is a cancer of the white blood cells. It is a form of leukemia characterized by the increased and unregulated growth of predominantly myeloid cells in the bone marrow and the accumulation of these cells in the blood. CML is a clonal bone marrow stem cell disorder in which proliferation of mature granulocytes (neutrophils, eosinophils, and basophils) and their precursors is the main finding. It is a type of myeloproliferative disease associated with a characteristic chromosomal translocation called the Philadelphia chromosome. CML is now largely treated with tyrosine kinase inhibitors (TKIs), such as imatinib, dasatinib, or nilotinib, which have led to dramatically improved survival rates since their introduction in the last decade.
This text uses material from Wikipedia and is available under the GNU Free Documentation License.
Latest Spotlight News
'Gap' for HIV vaccine efforts after latest setback
The hunt for an HIV vaccine has gobbled up $8 billion in the past decade, and the failure of the most recent efficacy trial has delivered yet another setback to 26 years of efforts.
Consuming coffee linked to lower risk of detrimental liver disease, study finds
Regular consumption of coffee is associated with a reduced risk of primary sclerosing cholangitis (PSC), an autoimmune liver disease, Mayo Clinic research shows. The findings were being presented at the Digestive Disease ...
Ketamine shows significant therapeutic benefit in people with treatment-resistant depression
Patients with treatment-resistant major depression saw dramatic improvement in their illness after treatment with ketamine, an anesthetic, according to the largest ketamine clinical trial to-date led by researchers from the ...
New research identifies risks, interventions for children's GI health
An increasing number of U.S. children are experiencing gastrointestinal issues that require interventions to resolve, according to research presented at Digestive Disease Week (DDW).
Returning genetic incidental findings without patient consent violates basic rights, experts say
Informed consent is the backbone of patient care. Genetic testing has long required patient consent and patients have had a "right not to know" the results. However, as 21st century medicine now begins to use the tools of ...
Vicious cycle: Obesity sustained by changes in brain biochemistry
With obesity reaching epidemic levels in some parts of the world, scientists have only begun to understand why it is such a persistent condition. A study in the Journal of Biological Chemistry adds substantially to the st ...
White matter imaging provides insight into human and chimpanzee aging
(Medical Xpress)—The instability of "white matter" in humans may contribute to greater cognitive decline during the aging of humans compared with chimpanzees, scientists from Yerkes National Primate Research ...
Melon focus headband turns to Kickstarter for rollout plans
(Medical Xpress)—What if the quality of your work depends more on your focus on the piano keys or canvas or laptop than your musical or painting or computing skills? If target users can be convinced, they ...
Temporal processing in the olfactory system
The neural machinery underlying our olfactory sense continues to be an enigma for neuroscience. A recent review in Neuron seeks to expand traditional ideas about how neurons in the olfactory bulb might encode information about ...
AIDS science at 30: 'Cure' now part of lexicon
Big names in medicine are set to give an upbeat assessment of the war on AIDS on Tuesday, 30 years after French researchers identified the virus that causes the disease.
